Zacks: Brokerages Expect Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Will Post Earnings of -$1.75 Per Share

Equities analysts predict that Diffusion Pharmaceuticals Inc. (NASDAQ:DFFNGet Rating) will announce ($1.75) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Diffusion Pharmaceuticals’ earnings, with estimates ranging from ($2.00) to ($1.50). Diffusion Pharmaceuticals posted earnings of ($3.00) per share in the same quarter last year, which suggests a positive year over year growth rate of 41.7%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($7.75) per share for the current year, with EPS estimates ranging from ($8.50) to ($7.00). For the next financial year, analysts anticipate that the business will post earnings of ($7.00) per share, with EPS estimates ranging from ($7.50) to ($6.50). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals (NASDAQ:DFFNGet Rating) last released its earnings results on Monday, March 21st. The company reported ($2.00) EPS for the quarter, hitting analysts’ consensus estimates of ($2.00).

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Diffusion Pharmaceuticals in a research report on Thursday, April 7th. StockNews.com assumed coverage on Diffusion Pharmaceuticals in a report on Thursday. They issued a “sell” rating for the company.

Shares of NASDAQ:DFFN opened at $7.15 on Thursday. The stock has a market cap of $14.59 million, a P/E ratio of -0.55 and a beta of 1.68. Diffusion Pharmaceuticals has a 52-week low of $5.10 and a 52-week high of $42.75. The business has a fifty day moving average of $19.38 and a two-hundred day moving average of $17.90.

A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Diffusion Pharmaceuticals in the 4th quarter worth approximately $46,000. Citadel Advisors LLC acquired a new stake in shares of Diffusion Pharmaceuticals in the second quarter valued at $110,000. Renaissance Technologies LLC lifted its holdings in shares of Diffusion Pharmaceuticals by 8.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,223,102 shares of the company’s stock valued at $373,000 after buying an additional 97,600 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Diffusion Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 858,408 shares of the company’s stock valued at $437,000 after buying an additional 54,118 shares during the period.

About Diffusion Pharmaceuticals (Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.

Featured Articles

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.